

Clinical Evidence and Translational Basis of a Specialized Four-Source Heme Iron Oral Supplement System

Jabar Yassine *, Fatima Al-Zahra, Gregg L. Semenza

World Food Supplement Association, New York, USA

*info@wfsas.org

Abstract

Background: Iron deficiency and iron-deficiency anemia remain highly prevalent, particularly among women of reproductive age, pregnant women, and patients with chronic disease. Oral iron is first-line therapy in most settings, yet its performance is frequently constrained by gastrointestinal intolerance, variable absorption, and poor adherence. The specialized four-source system discussed here combines heme iron, ferrous bisglycinate, ferrous gluconate, ferrous lactate, and vitamin C-rich botanical extracts with the intention of broadening uptake pathways and improving formulation robustness. **Objective:** We evaluated the translational plausibility of this formulation by retaining the quantitative preclinical evidence from its technical dossier and integrating it with published human clinical trial data relevant to its component strategy. **Methods:** We extracted the dossier-reported data on vitamin C retention, dissolution, intestinal absorption, hemoglobin recovery, and ferritin recovery. We then reviewed publicly available randomized trials, meta-analyses, and practice updates through March 2026 focusing on heme iron polypeptide, ferrous bisglycinate, conventional oral iron salts, vitamin C coadministration, and oral iron dosing frequency. **Results:** The retained dossier data showed superior 6-month vitamin C retention (93.25% vs 65.17% in the synthetic control), higher 60-minute cumulative dissolution (98.26% vs 76.54%-96.18% in comparators), greater rat intestinal iron absorption (38.72% vs 8.64%-29.43%), and stronger recovery of hemoglobin and ferritin in the iron-deficiency model. In public human studies, ferrous bisglycinate repeatedly showed favorable tolerability and, in pregnancy-related settings, stronger or noninferior hematologic performance relative to conventional salts; a 2023 meta-analysis of 17 randomized trials reported higher hemoglobin in pregnant women and fewer gastrointestinal adverse events. By contrast, heme iron polypeptide did not consistently outperform conventional oral iron in chronic kidney disease or post-bariatric surgery settings. Routine vitamin C coadministration provided little clinically meaningful additional benefit over oral iron alone, whereas alternate-day or once-daily oral dosing appeared physiologically advantageous in some women. **Conclusions:** The four-source system has a coherent mechanistic and preclinical rationale, but current public human evidence supports some components more strongly than others. At present, the most defensible clinical proposition is improved tolerability and complementary absorption pathways rather than universal superiority over all oral iron products.

Keywords

Iron deficiency; iron-deficiency anemia; heme iron; ferrous bisglycinate; oral iron; vitamin C; gastrointestinal tolerability; translational medicine.

1. Introduction

Iron deficiency remains one of the most prevalent nutritional disorders worldwide. Recent WHO estimates indicate that anaemia affects 30% of women aged 15-49 years and 37% of pregnant women globally, and iron deficiency continues to be one of its most important treatable drivers. In adults, the burden of iron deficiency extends beyond frank anemia, with many patients experiencing fatigue, reduced exercise tolerance, impaired concentration, restless legs syndrome, or reduced quality of life before hemoglobin falls substantially.

Oral iron is still first-line therapy for most patients with iron deficiency. However, conventional ferrous salts present well-recognized limitations. Gastrointestinal adverse effects, including nausea, bloating, constipation, altered bowel habits, and black stool, impair adherence. In parallel, absorption from a single formulation can vary markedly depending on food intake, inflammation, hepcidin physiology, baseline iron status, and coexisting gastrointestinal disease. The specialized four-source heme iron system discussed in this article attempts to address these limitations through a multi-pathway design. Heme iron is intended to provide a distinct uptake route; ferrous bisglycinate contributes a chelated form with an established tolerability advantage in several settings; ferrous gluconate and ferrous lactate contribute readily ionizable iron; and the botanical vitamin C-rich module is intended to support stability and dissolution performance.

We therefore approached the formulation not as a simple mixture of iron sources, but as a coordinated system linking different absorption modes, different release profiles, and a stability-support matrix. To evaluate whether this concept has real translational merit, we retained the quantitative preclinical evidence from the source technical dossier and integrated it with public clinical trial data on analogous ingredients and dosing strategies.

2. Materials and Methods

2.1. Retained source materials and data extraction

We retained the core quantitative results reported in the technical dossier, including 6-month vitamin C retention, 60-minute cumulative dissolution, rat in situ intestinal absorption, hemoglobin recovery, and serum ferritin recovery. We also preserved the two original graphics depicting stability and intestinal absorption so that the mechanistic and preclinical sections of this manuscript remained continuous with the underlying formulation dossier.

2.2. Public clinical evidence retrieval

We searched PubMed, PubMed Central, and WHO public resources through March 2026. Priority was given to randomized controlled trials, systematic reviews, meta-analyses, and high-quality practice updates directly relevant to the formulation logic: heme iron polypeptide, ferrous bisglycinate, conventional oral ferrous salts, vitamin C administered with oral iron, and alternate-day versus daily dosing.

2.3. Evidence synthesis framework

Rather than treating the public human studies as direct proof of the present formulation, we mapped them onto four component-level evidence domains: heme-iron transport, chelated-iron performance, ionic iron-salt performance, and adjunctive formulation or dosing modifiers. This framework allowed us to identify which parts of the formulation strategy are already supported by human evidence and which parts still require product-specific randomized validation.

3. Results

3.1. Retained preclinical and bench evidence from the technical dossier

The retained source-dossier data suggest a coherent front-end advantage across stability, dissolution, and absorption. The vitamin C retention curve indicates that the natural extract system maintained 93.25% retention at 6 months, compared with 65.17% for the synthetic vitamin C control. Dissolution testing showed a 60-minute cumulative dissolution of 98.26%, exceeding most comparators. The rat in situ intestinal absorption experiment then showed substantially higher intestinal iron uptake than the comparator formulations. In parallel, the iron-deficiency model demonstrated stronger recovery of hemoglobin and serum ferritin. Taken together, these data support the view that the formulation’s value lies not in a single isolated readout, but in a connected chain extending from stability to dissolution, absorption, and hematologic restoration.

Table 1 Quantitative evidence retained from the technical dossier

Metric	Current system	Comparator 1	Comparator 2	Comparator 3
Vitamin C retention at 6 months (%)	93.25	-	-	65.17
60-min cumulative dissolution (%)	98.26	76.54	82.41	96.18
Rat intestinal iron absorption (%)	38.72 ± 2.15	8.64 ± 1.03	22.58 ± 1.76	29.43 ± 1.94
Hemoglobin after 28 days (g/L)	139.76 ± 7.82	105.63 ± 7.15	121.47 ± 7.53	128.59 ± 7.64
Serum ferritin after 28 days (µg/L)	112.58 ± 12.69	58.72 ± 8.45	76.39 ± 9.58	88.46 ± 10.23




Figure 1 Vitamin C retention during accelerated stability testing




Figure 2 Rat in situ intestinal iron absorption

3.2. Published human clinical evidence relevant to the formulation strategy

Among the human evidence domains, ferrous bisglycinate is the most consistently supported component. In a 2022 randomized controlled trial in 120 pregnant women with iron deficiency, 24 mg elemental iron as ferrous bisglycinate with folic acid and multivitamins was compared with 66 mg elemental iron as ferrous fumarate. Both groups improved significantly at 3 and 6 months, but the ferrous bisglycinate formulation produced higher immediate serum iron responses and fewer reports of nausea, abdominal pain, bloating, constipation, and metallic taste. In a 2014 Danish double-blind trial, 25 mg elemental iron as ferrous bisglycinate was not inferior to 50 mg elemental iron as ferrous sulfate for preventing iron deficiency and iron-deficiency anemia during pregnancy, while gastrointestinal complaints were lower in the bisglycinate arm. More broadly, a 2023 meta-analysis of 17 randomized trials found that ferrous bisglycinate was associated with higher hemoglobin and fewer gastrointestinal adverse events among pregnant women.

At the same time, ferrous bisglycinate does not appear to be categorically superior at any low dose in every population. In a 2023 randomized noninferiority trial in 480 Cambodian women, most of whom were not iron deficient at baseline, 60 mg ferrous sulfate produced higher ferritin concentrations at 12 weeks than 18 mg ferrous bisglycinate, and no differences were observed in gut inflammation or enteropathogen detection. This trial is important because it shows that higher bioavailability does not automatically compensate for lower dose or for low baseline deficiency prevalence.

The human evidence on heme iron is more mixed. In the 2012 HEMATOCRIT trial in peritoneal dialysis patients, heme iron polypeptide did not improve transferrin saturation relative to ferrous sulfate and was associated with lower ferritin at 6 months. In a 2018 randomized trial after Roux-en-Y gastric bypass, ferrous sulfate raised hemoglobin from 10.8 to 13.0 g/dL and ferritin from 4.9 to 15.5 $\mu\text{g/L}$, whereas heme iron polypeptide produced no significant change in the major biomarkers. These data argue against assuming that heme iron alone will universally outperform conventional oral ferrous formulations, especially in complex absorption-impaired populations.

The evidence on vitamin C coadministration is also instructive. In the 2020 JAMA Network Open trial enrolling 440 adults with iron-deficiency anemia, oral iron plus vitamin C was equivalent to oral iron alone for hemoglobin recovery, ferritin improvement, and adverse events. A 2024 systematic review and meta-analysis reached a similar conclusion, observing only a small and

likely clinically insignificant increase in hemoglobin when vitamin C was added to oral iron. In practical terms, this suggests that vitamin C is better justified as a formulation-support factor for stability and dissolution than as a mandatory companion therapy.

Dosing frequency is another clinically relevant modifier. The 2017 and 2020 studies by Stoffel and colleagues showed that consecutive-day or split dosing can increase serum hepcidin and reduce subsequent absorption, whereas alternate-day or single daily dosing may improve fractional absorption in women with iron depletion or iron-deficiency anemia. This finding implies that the success of a multi-source oral iron system will depend not only on its composition but also on how it is dosed.

Table 2 Published human clinical evidence relevant to the formulation strategy

Study	Population / N	Intervention	Duration	Main findings
Li 2020	Adults with IDA, n=440	Oral iron + vitamin C vs oral iron alone	8 weeks	Hb change at 2 weeks: 2.00 vs 1.84 g/dL; ferritin change at 8 weeks: 35.75 vs 34.48 ng/mL; adverse events: 20.9% vs 20.5%; groups were equivalent.
Bumrungpert 2022	Pregnant women with iron deficiency, n=120	24-mg elemental iron as ferrous bisglycinate formulation vs 66-mg ferrous fumarate	6 months	Both groups significantly improved Hb and ferritin; the bisglycinate formulation showed higher immediate serum iron and fewer nausea, abdominal pain, bloating, constipation, and metallic taste reports.
Milman 2014	Danish pregnant women, n=80	25-mg ferrous bisglycinate vs 50-mg ferrous sulfate	Until delivery	Noninferior to ferrous sulfate for prevention of ID and IDA; gastrointestinal complaints were lower (P=0.001).
Fischer 2023 RCT	Nonpregnant women, n=480	18-mg ferrous bisglycinate vs 60-mg ferrous sulfate vs placebo	12 weeks	Mean ferritin at 12 weeks: 84 vs 99 vs 78 µg/L; low-dose bisglycinate was not noninferior to ferrous sulfate; no gut inflammation differences.
Fischer 2023 meta-analysis	17 RCTs	Ferrous bisglycinate vs other oral iron supplements	4-20 weeks	Among pregnant women, Hb was higher (SMD 0.54, 95% CI 0.15-0.94) and GI adverse events were fewer (IRR 0.36, 95% CI 0.17-0.76).
Barraclough 2012	Peritoneal dialysis patients, n=62	Heme iron polypeptide vs ferrous sulfate	6 months	Median TSAT 22% vs 20% (P=0.65); ferritin was lower in the heme-iron group (P=0.003); no clear clinical benefit.
Mischler 2018	Women post-RYGB, n=14	FeSO ₄ 195 mg/day vs heme iron polypeptide 31.5-94.5 mg/day	8 weeks	FeSO ₄ raised Hb from 10.8 to 13.0 g/dL and ferritin from 4.9 to 15.5 µg/L; the heme-iron arm showed no significant biomarker improvement.

Study	Population / N	Intervention	Duration	Main findings
Nagaraju 2013	Non-dialysis CKD, n=40	Heme iron polypeptide vs intravenous iron sucrose	6 months	Hb at 6 months: 117 vs 113 g/L (P=0.37); TSAT was similar; ferritin was higher with IV iron (244 vs 85.5 µg/L, P=0.004).
Stoffel 2017/2020	Women with iron depletion or IDA	Consecutive daily dosing vs alternate-day/single dosing	Short-term absorption studies	Alternate-day or single daily dosing produced higher absorption; consecutive dosing induced a 24-hour hepcidin rise.

3.3. Clinical interpretation for the present formulation

When the retained preclinical data are interpreted alongside the public human literature, the strongest clinical reading of this formulation is not that any one component is universally superior to all other iron products. Rather, the formulation appears most credible as a complementary system: ferrous bisglycinate contributes tolerability and relatively stable uptake, heme iron provides an additional absorption pathway, conventional ferrous salts contribute rapidly available ionic iron, and the botanical vitamin C-rich module supports stability and dissolution. This evidence architecture is consistent with the dossier's stepwise improvement from formulation robustness to hematologic recovery.

4. Discussion

From a translational perspective, the value of a multi-source iron system depends on functional differentiation rather than theoretical ingredient stacking. The public evidence indicates that such differentiation is plausible here. Ferrous bisglycinate has the clearest human tolerability signal, particularly in pregnancy-related studies. Conventional ferrous salts retain practical importance for restoring iron stores, despite their side-effect burden. Heme iron does not show universal superiority in trials, but its distinct uptake route still makes it a defensible complementary component within a mixed system.

The public literature also defines two important boundary conditions. First, baseline iron status matters. In participants with low deficiency prevalence or in studies using much lower elemental doses, a more bioavailable chelate may still not outperform higher-dose conventional salts in ferritin repletion. Second, special populations cannot be managed by formulation logic alone. Patients with chronic kidney disease, active inflammation, or altered post-surgical anatomy may remain better served by intravenous iron or individualized treatment algorithms. For that reason, the next decisive step for this four-source system is not additional bench optimization alone, but a product-specific randomized trial. The most informative study population would be adults with mild-to-moderate iron deficiency or iron-deficiency anemia who still qualify for oral therapy. A well-designed study should evaluate hemoglobin, ferritin, transferrin saturation, gastrointestinal tolerability scores, adherence, and discontinuation rates, while also comparing once-daily with alternate-day dosing. Only that level of evidence can convert the current chain of mechanistic plausibility, retained preclinical strength, and component-level clinical support into a direct clinical claim for the product itself.

5. Limitations

This article has three main limitations. First, the human evidence cited here pertains to publicly studied formulations analogous to the components of the present system rather than to a completed registered trial of this exact product. Second, the retained preclinical dossier data

have not yet been externally replicated by an independent research group. Third, the public studies differ substantially in population, baseline iron status, elemental iron dose, dosing frequency, and comparator formulation, so they are best used to judge evidentiary direction rather than to infer a single universal effect size.

6. Conclusion

In our view, the specialized four-source heme iron oral supplement system has a strong formulation logic and a credible translational foundation. The retained source-dossier evidence supports advantages in stability, dissolution, absorption, and hematologic recovery, while the public clinical literature supports the relevance of chelated-iron tolerability, absorption-pathway complementarity, and dosing optimization. The most balanced current conclusion is that this system has meaningful potential as a differentiated oral iron strategy, especially where tolerability, adherence, and multi-pathway absorption are priorities. Its definitive clinical advantage in a target population, however, still requires confirmation in a product-specific randomized controlled trial.

References

- [1] World Health Organization. Anaemia. WHO Fact Sheet. Updated 2025.
- [2] Auerbach M, DeLoughery TG, Tirnauer JS. Iron Deficiency in Adults: A Review. *JAMA*. 2025; 333(20): 1813-1823. doi:10.1001/jama.2025.0452.
- [3] Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS One*. 2015;10(2):e0117383. doi:10.1371/journal.pone.0117383.
- [4] Li N, Zhao G, Wu W, et al. The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial. *JAMA Netw Open*. 2020; 3(11):e2023644. doi:10.1001/jamanetworkopen.2020.23644.
- [5] Deng J, Ramelli L, Li PY, et al. Efficacy of vitamin C with Fe supplementation in patients with iron deficiency anemia: a systematic review and meta-analysis. *Blood Vessel Thromb Hemost*. 2024;1(4):100023. doi:10.1016/j.bvth.2024.100023.
- [6] Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR. Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. *Nutrients*. 2022;14(3):452. doi:10.3390/nu14030452.
- [7] Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. *J Perinat Med*. 2014;42(2):197-206. doi:10.1515/jpm-2013-0153.
- [8] Fischer JA, Pei LX, Elango R, et al. Is a Lower Dose of More Bioavailable Iron (18-mg Ferrous Bisglycinate) Noninferior to 60-mg Ferrous Sulfate in Increasing Ferritin Concentrations While Reducing Gut Inflammation and Enteropathogen Detection in Cambodian Women? A Randomized Controlled Noninferiority Trial. *J Nutr*. 2023;153(8):2453-2462. doi:10.1016/j.tjnut.2023.05.029.
- [9] Fischer JA, Ashorn U, Arimond M, et al. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev*. 2023;81(12):1533-1549. doi:10.1093/nutrit/nuac106.
- [10] Barraclough KA, Brown F, Hawley CM, et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. *Nephrol Dial Transplant*. 2012;27(11):4146-4153. doi:10.1093/ndt/gfs372.
- [11] Mischler RA, Armah SM, Craig BA, et al. Comparison of Oral Iron Supplement Formulations for Normalization of Iron Status Following Roux-EN-y Gastric Bypass Surgery: a Randomized Trial. *Obes Surg*. 2018;28(2):369-377. doi:10.1007/s11695-017-2858-4.

- [12] Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. *BMC Nephrol.* 2013;14:64. doi:10.1186/1471-2369-14-64.
- [13] Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. *Lancet Haematol.* 2017;4(11):e524-e533. doi:10.1016/S2352-3026(17)30182-5.
- [14] Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. *Haematologica.* 2020;105(5):1232-1239. doi:10.3324/haematol.2019.220830.
- [15] DeLoughery TG, Jackson CS, Ko CW, Rockey DC. AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review. *Clin Gastroenterol Hepatol.* 2024;22(8):1575-1583. doi:10.1016/j.cgh.2024.03.046.
- [16] Specialized four-source heme iron-glycine chelated iron technical dossier, on file.